Ezurpimtrostat is under clinical development by Genoscience Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ezurpimtrostat’s likelihood of approval (LoA) and phase transition for Bile Duct Cancer (Cholangiocarcinoma) took place on 08 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ezurpimtrostat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ezurpimtrostat overview

Ezurpimtrostat (GNS-561) is under development for the treatment of coronavirus disease 2019 (COVID-19), glioblastoma multiforme (GBM), gynaecological cancer, liver cancer, metastatic hepatocellular carcinoma and liver fibrosis. The drug candidate is administered orally as a capsule formulation and also as an intraarterial route (TACE). The drug candidate is a new chemical compound and is an autophagy inhibitor that targets and kill cancer stem cells (CSCs). It also acts by targeting transforming growth factor beta 1 (TGF-B1) and palmitoyl protein thioesterase (PPT-1). 

It was under development for the treatment of bile duct cancer (cholangiocarcinoma), metastatic hepatocellular carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer

Genoscience Pharma overview

Genoscience Pharma (Genoscience) is a pharmaceutical company that develops new proprietary chemical compounds against cancer stem cells. The company discovers and develops novel therapeutic products for alternative treatment of acute myeloid leukemia and GNS561 to treat hepatocarcinoma. Its products portfolio include BL-8030, GNS 396, GNS XXX and GNS 561. Genoscience’s product indicates therapy to Hepatitis C Virus infections; HCV protease inhibitor; anti CSC in acute myeloid leukemia; and anti CSC in hepatitis C cells. The company’s CSCs such as GNS396 and GNS561 could be combined with chemotherapy drugs to rise the remission time and reduce the relapse frequency in cancer patients. It collaborates with biotechnology companies to develop protease inhibitors and treatment of Hepatitis C. Genoscience is headquartered in Marseille, France.

Quick View Ezurpimtrostat LOA Data

Report Segments
  • Innovator
Drug Name
  • Ezurpimtrostat
Administration Pathway
  • Intraarterial
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.